Mirum Pharmaceuticals, Inc.

Good afternoon. My name is Chris, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Miriam Q2 2022 business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, then the number one on your telephone keypad. To withdraw your question, please press star one again. Thank you. Ian Clements, Chief Financial Officer. You may begin.

Thanks, Chris. Good afternoon, everyone. I'd like to welcome you to Miriam Pharmaceuticals' second quarter 2022 conference call. I'm joined today by our President and CEO, Chris Peets, our Chief Operating Officer, Peter Radovich, and our Head of R&D, Pam Vig. Earlier this afternoon, Miriam issued a news release announcing the company's results for the second quarter of 2022. Copies of this news release and SEC filings can be found in the Investors section of our website. Before we begin, we'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements about MIRM and our programs based on management's current expectations, including statements regarding MIRM's business plans, development programs, strategies, prospects, market opportunities, and financial forecasts and guidance. MIRM is under no duty to update these statements, and they are subject to numerous risks and uncertainties, and actual results could differ materially from the results anticipated by these statements. Investors should read the risk factors set forth in Miriam's 10-K for the year ended December 31st, 2021, and any subsequent reports filed with the SEC. With that said, I'd like to turn the call over to Chris. Chris?

Thank you, Ian, and good afternoon to everyone.